Therapy and Outcomes of Patients with Relapsed Nonmetastatic Rhabdomyosarcoma: A Report from the French Society of Pediatric Oncology Malignant Mesenchymal Tumor Committee.

ABSTRACT:

Background

The prognosis for patients with relapse of localized rhabdomyosarcoma (RMS) remains poor, with limited evidence for optimal second-line therapy. This study describes the management and outcomes of relapsed RMS patients in France.

Methods

We retrospectively reviewed all nonmetastatic RMS patients enrolled in France in the RMS 2005 study who relapsed between 2006 and 2019 after achieving complete local control, defined as complete remission or stable residue ≥ 6 months after treatment completion. Data were extracted from the RMS 2005 database and medical records.

Results

Ninety-five patients relapsed at a median age of 6.0 years (range: 1.0-27.0). The median time from diagnosis to relapse was 17.5 months (range: 7.4-82.0). Most patients had embryonal RMS (65.

SUBMITTER: Sevrin F 

PROVIDER: S-EPMC11605160 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature